Bayer

Bayer started as a small German synthetic dye manufacturer. In the late 19th century, the company’s chemists discovered that many of the chemical properties used in dyes were also useful in medicine. This research eventually led to the 1899 patenting of Aspirin, the most famous drug in history. Aspirin made Bayer a global household name and established the company as a pillar of the early German chemical and pharmaceutical export machine.

In the most controversial corporate move of the decade, Bayer spent $63 billion to acquire the American agricultural giant Monsanto. The goal was to unify Bayer’s chemical expertise with Monsanto’s massive footprint in seeds and pesticides, creating a global leader in "life sciences." However, the deal was an immediate public relations and legal disaster. Monsanto brought with it massive, long-term liabilities related to its weed-killer Roundup, which faced thousands of lawsuits alleging it caused cancer.

The Roundup litigation spiraled into an existential corporate crisis. Bayer’s stock price plummeted as it was forced to pay out billions of dollars in settlements. The company’s management team faced a fierce revolt from activist investors who argued that the Monsanto deal had been a catastrophic strategic failure. The firm was forced to slash its dividend, initiate massive workforce reductions, and undergo a total operational restructuring to pay down the debt incurred by the acquisition.

Under intense pressure, Bayer began a multi-year effort to stabilize its balance sheet. It exited several non-core business lines and focused heavily on scaling its high-growth, specialized biotech R&D programs, specifically in cardiovascular and rare-disease therapies. The company’s strategy shifted to proving that its core pharmaceutical research was still elite, despite the massive, ongoing weight of the agricultural litigation.

By mid-2026, Bayer has emerged from its most turbulent period in decades. While the company still deals with the tail-end of its agricultural legal liabilities, its pharmaceutical and health-science divisions are operating with high efficiency. The firm remains a unique, sprawling conglomerate that successfully bridged the gap between complex pharmaceutical research and global agricultural supply, maintaining its status as a vital, if historically controversial, industrial institution.